GTC Gets Broad Transgenic Milk Patent
GTC Biotherapeutics Inc., the Framingham-based company that was acquired by LFB Biotechnologies SAS last year, announced that it has been granted a patent covering any production of therapeutic protein in the milk of transgenic animals.
The patent, granted by the U.S. Patent and Trademark Office, extends to 2027.
GTC said it has also received a new U.S. patent for its lead product, ATryn, an anticoagulant and anti-inflammatory product derived from the milk of genetically modified goats. The new patent relates to a method of treatment of patients with a particular protein deficiency or inflammation.
GTC said ATryn is the only transgenically produced therapeutic protein that has been approved by both the U.S. Food and Drug Administration and the European Medicines Agency.
GTC was acquired by LFB, which is based in France, in December 2010.
WBJ Web Partners
Most Recent
Most Recent
0 Comments